Table 1 Characteristics of 71 patients with advanced non-small-cell lung cancer
From: Combinatory effect of BRCA1 and HERC2 expression on outcome in advanced non-small-cell lung cancer
N (%) | |
|---|---|
Age median (range) | 63 (40–82) |
Gender | |
Male | 54 (76) |
Female | 17 (24) |
ECOG PS | |
0 | 9 (13) |
1 | 44 (62) |
2 | 13 (18) |
No data | 5 (7) |
Smoking status | |
Current smoker | 31 (44) |
Former smoker | 29 (41) |
Never smoked | 11 (15) |
Histology | |
Adenocarcinoma | 43 (60) |
Squamous cell carcinoma | 14 (20) |
Large cell carcinoma | 14 (20) |
First-line treatment | |
Cisplatin-gemcitabine | 32 (45) |
Carboplatin-gemcitabine | 19 (27) |
Cisplatin-pemetrexed | 10 (14) |
Carboplatin-pemetrexed | 10 (14) |
Second-line treatment | |
Taxanes | 11 (15) |
EGFR TKIs | 22 (31) |
Others | 9 (13) |
Response rate | |
Complete response | 0 (0) |
Partial response | 27 (38) |
Stable disease | 26 (37) |
Progressive disease | 11 (30) |
No data | 7 (10) |